You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy

    SBC: SIGNAL SOLUTIONS, LLC            Topic: NINDS

    EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy There is an urgent need for research into treatment options for epilepsy and other seizure disorders. Animal models are increasingly used to understand disease mechanisms and to screen promising therapeutic approaches. Animal epilepsy model use typically requires expensive and labor-intensive experimentation, with invasive EE ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

    SBC: Eigen Health Services LLC            Topic: 102

    Project Summary Prostate cancer is one of the most commonly occurring forms of cancer, accounting for 21% of all cancer in men. The Prostate Imaging Reporting and Data System (PI-RADS) aims to standardize reporting of prostate cancer using multi-parametric magnetic resonance imaging (mpMRI). However, the in-depth analysis, as demanded by PI-RADS, remains challenging due to the complexity and heter ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  6. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

    SBC: KS & ASSOCIATES LLC            Topic: NIEHS

    PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Neurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government